With 28 R&D centers across 12 countries and over 2,000 R&D employees, the company turns deep tech into tangible features that anticipate how people want to live

ISTANBUL, March 26, 2026 /PRNewswire/ — Beko, a leading home appliances company, is accelerating its technology leadership by harnessing a global research and development ecosystem designed to turn emerging science into sustainable, smart and digitally secure home solution, from AI-powered refrigerators to advanced technologies that preserve the vitamins in fresh food for longer, and much more.

Nihat Bayız, Beko Chief Production and Technology Officer

By positioning R&D among the fundamental engines of its growth, Beko is able to bridge the gap between deep-tech exploration and the tangible features that anticipate how people want to live. Beko’s R&D capabilities find their strength in a unified global network of 28 R&D centers across 12 countries, creating a collaborative nucleus that stretches from its core in Türkiye – where 13 centers are located – to key European hubs in Italy, Poland, Slovakia and Romania. This distributed yet tightly connected model allows engineering and design teams to work as one, so ideas can move quickly from early research to built–in product solutions that are interoperable by design and create real value in everyday life, with Italy’s Cassinetta and Fabriano hubs playing a pivotal role in driving design and built–in innovation at the heart of Europe’s home appliances ecosystem.

The efficacy of Beko’s R&D infrastructure is validated by more than 4,500 international patent applications and over one million annual tests conducted to provide peak reliability and performance. To further accelerate this development, Beko has integrated AI and digital technologies into its core processes. By applying machine learning to materials research to predict structural performance and leveraging generative AI for faster software design and development, the company ensures that its technical foundation remains as agile as the evolving consumer needs it aims to meet.

From lab to kitchen: Innovation in Action

The ultimate proof of concept for Beko’s R&D investment and global infrastructure is found in the products themselves, which serve as the direct outcome of Beko’s scientific rigor. These innovations are exemplified by technologies such as HarvestFresh, which uses a unique three-color light system to mimic the natural 24-hour sun cycle and preserve vitamins in fresh produce¹, and Beko’s AI-Sense and HomeWhiz enabled appliances. These systems serve as a tangible demonstration of the R&D network’s capabilities, using artificial intelligence to learn household usage patterns, optimize refrigerator performance, and track energy consumption. Through this unified approach, Beko ensures that every investment in its more than 2,000 R&D employees, together with its global centers, results in meaningful products that remain at the forefront of modern home living.

Reflecting on this roadmap-driven approach, Nihat Bayız, Chief Production and Technology Officer at Beko stated: “Our ambition is to be a company that doesn’t just adopt technology but develops it and brings it to homes around the world. By carefully balancing our short-, mid- and long–term innovation horizons, we can turn deep R&D insight into scalable solutions that stay ahead of evolving consumer needs. Whether it is AI learning how a family uses their fridge to save energy, or light that helps preserve vitamins in fresh food, our teams are focused on transforming investment into innovation that genuinely improves everyday life.”

About Beko

Beko is an international home appliance company with a strong global presence, operating through subsidiaries in more than 55 countries with a workforce of around 45,000 employees and production facilities spanning multiple regions—including Europe, Asia, Africa, and the Middle East. Beko has 22 brands owned or used with a limited license (Arçelik, Beko, Whirlpool*, Grundig, Hotpoint, Arctic, Ariston*, Leisure, Indesit, Blomberg, Defy, Dawlance, Hitachi*, Voltas Beko, Singer*, ElektraBregenz, Flavel, Bauknecht, Privileg, Altus, Ignis, Polar). Beko is the largest white goods company in Europe with its market share (based on volumes) and reached a consolidated turnover of 10.7 billion Euros in 2025. Beko’s 28 R&D and Design Centers & Offices across the globe are home to over 2,000 R&D employees and hold more than 4,500 international registered patent applications to date. The company has achieved the highest score in the S&P Global Corporate Sustainability Assessment (CSA) in the DHP Household Durables industry for the seventh consecutive year (based on the results dated 16 October 2025).** The company has been recognized as the 17^th most sustainable company on TIME Magazine and Statista’s 2025 list of the World’s Most Sustainable Companies. Beko’s vision is ‘Respecting the World, Respected Worldwide.’  

www.bekocorporate.com  

*Licensee limited to certain jurisdictions.  
**The data presented belongs to Arçelik A.Ş., a parent company of Beko.  

¹ Tested by Intertek based on Vitamin C and Vitamin A measurements in tomatoes, green peppers, carrots, spinach, celery, parsley, coriander, red peppers and kale directly exposed to the light technology compared with Day 0 conditions over a 5-day period.

Equipped with DJI’s flagship 1-inch imaging, O4+ video transmission, and omnidirectional obstacle sensing, creators can now film 360 footage in 8K with ease

SHENZHEN, China, March 26, 2026 /PRNewswire/ — DJI, the global leader in civilian drones and creative camera technology, today launches Avata 360. Designed to unlock endless creativity in one take^[1], DJI’s new 8K 360° flagship drone delivers 360° imaging with 1-inch-equivalent sensors^[1] for filming in 8K/60fps HDR video. Meanwhile, DJI’s powerful O4+ video transmission system and obstacle sensing^[1] enable creators to see farther with a more stable, safer, and more immersive flight experience. Paired with DJI goggles and motion controllers, the latest addition to the popular Avata series delivers an immersive 360° flight experience for FPV thrills. Creators can also use DJI remote controllers to capture a full 360° view in a single flight that can be reframed from any perspective, transforming a single take into multiple creative possibilities.

Brilliant Imaging, Boundless Creativity

Avata 360 offers two different lenses that can be seamlessly switched. The 360° lens uses 1-inch-equivalent sensors^[1] that can capture 360° images in rich detail for 8K/60fps HDR videos^[1] and 120 MP photos. With the large 2.4 μm pixels and high dynamic range, light and shadow are also captured with exquisite clarity. Both video and photos can be exported directly or reframed in post-production. Meanwhile, the Single Lens mode allows creators to use the classic Avata-style filming in 4K/60fps^[1].

Powerful Video Transmission, Immersive Flight

Avata 360 leverages DJI’s flagship O4+ video transmission system to deliver stable and clear live feeds for smoother, more immersive flights. Its strong anti-interference capabilities enable high-definition, high-frame-rate transmission at 1080p/60fps and support a range of up to 20 km^[1].

Fly With Confidence, Create With Ease

Avata 360 offers up to 23 minutes of flight time^[1] and includes several standard safety features, including nightscape omnidirectional obstacle sensing^[1] and integrated propeller guards. If damaged, the camera lens can be easily replaced with the DJI Avata 360 replacement lens kit with tools (sold separately). It also brings an exceptional experience to aerial content creation, where a single shot with the drone’s 360° imaging can be transformed into multiple, masterful creations through post production using the DJI Fly and DJI Studio apps, including:

• Spotlight Free^[1] – Locks onto a moving subject and assists with camera movement, replicating the sophisticated camera language like a pro with Inspire 3. By comparison, Spotlight locks onto your subject’s face to effortlessly capture Circle or Dronie shots without manual adjustments.
• ActiveTrack 360°^[1] – Automatically selects the optimal tracking mode. For example, Standard mode maintains a steady distance and altitude relative to the subject. Meanwhile, Cycling mode reacts faster to turns and keeps the subject in frame even in complex environments.
• FPV mode – Enables even novice pilots to adds a natural roll effect to Spotlight Free, ActiveTrack 360°, and manual flights to create dynamic, high-speed FPV-style footage. This mode can be applied in post-production.
• Intelligent Tracking – Powered by advanced algorithms, DJI Fly and DJI Studio apps make it effortless to lock onto and smoothly track people, vehicles, pets, and more, even in 360° footage.
• New One-Tap In-App Editing – With GyroFrame, 360° footage can be adjusted to an ideal angle and exported in the DJI Fly app. Both DJI Fly and DJI Studio allow camera movement effects to be added.
• Virtual Gimbal^[1] – Uses a 360° view to enable infinite rotation and tilt for dynamic camera moves. Even when flying in one direction, horizons can be rotated, and perspectives can be shifted to look back or perform a flip.
• Replaceable Front Lens Element – The front element features a replaceable design. Purchase a replacement lens kit with tools^[1], and you can easily replace the old lens yourself—no need to send it in for repair.
• 42GB Internal Storage and High-Speed Transfers – With 42GB of internal storage, 30 minutes of 360° video in 8K without a microSD card. Using Wi-Fi 6 High-Speed Transfer, 1 GB of footage can be transferred to the DJI Fly app in 10 seconds at up to 100 MB/s^[1].

FPV Flights and Aerial Filming in One Drone

Avata 360 combines the creative freedom of a 360 camera with the thrill of FPV flying like never before. It can be flown with DJI remote controllers (RC 2, RC-N2, RC-N3) for precise camera movement, allowing creators to unlock new ways to create stunning aerial shots. Meanwhile, DJI goggles and motion controllers offer a more immersive flight experience with 360° imaging at 1080p/60fps. Like the Avata 2, aerial acrobatics like drifting can be performed – even by beginners – with the DJI RC Motion 3. 

Price and Availability

DJI Avata 360 is available for pre-order starting today through store.dji.com and authorized retailers. Shipping begins April 2026 and will vary by region. Pricing and configurations are as follows:

• DJI Avata 360 (Drone Only) retails for £409.
• DJI Avata 360 (DJI RC 2) retails for £639.
• DJI Avata 360 Fly More Combo (DJI RC 2) retails for £829.
• DJI Avata 360 Motion Fly More Combo retails for £829.

DJI Care Refresh

DJI Care Refresh, the comprehensive protection plan for DJI products, is now available for DJI Avata 360. The replacement service covers accidental damage, including flyaway, collisions and water damage. For a small additional charge, you can have your damaged product replaced if an accident occurs.

DJI Care Refresh (1-Year Plan) includes up to two replacements in one year. DJI Care Refresh (2-Year Plan) includes up to four replacements in two years. Other services of DJI Care Refresh include official Warranty and free shipping. For a full list of details, please visit: https://www.dji.com/support/service/djicare-refresh.

For more information, please refer to: https://www.dji.com/avata-360

^[1] Only supported by certain camera modes or with specific accessories. All data was measured using a production model of DJI Avata 360 in a controlled environment; actual experience may vary. For more information, please refer to https://www.dji.com/avata-360.

SUZHOU, China, March 26, 2026 /PRNewswire/ — Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced its annual results for the year ended December 31, 2025 on March 25, 2026.

During the year, the Group delivered steady revenue growth and continued improvement in operating efficiency, while advancing multiple key pipeline programs. Against a dynamic industry backdrop, the Group’s core business demonstrated increasingly resilience. The Neurointerventional Business emerged as a stronger earnings contributor, while the Transcatheter Valve Therapeutic Business continued to expand its platform, enhance commercialization capabilities and improve its profitability profile.

Steady Growth with Improving Profitability Profile

For the year ended December 31, 2025, the Group recorded total revenue of RMB712.9 million, representing a year-on-year increase of 15.8%. Revenue contribution remained balanced, with TAVR-related products accounting for 40.7% and neurointerventional products accounting for 59.3% of total revenue.

While maintaining a relatively stable gross margin, the Group continued to strengthen cost discipline and improve operating efficiency, supported by scale expansion and more focused resource allocation. Excluding the losses attributable to the entities comprising the Future Technology Business ^[1], the Group’s adjusted loss for the year narrowed by 44.1% year on year to RMB110.5 million, reflecting a clear trend of improving underlying profitability.

Neurointerventional Business: Profit Contribution Accelerates and Globalization Begins

The Neurointerventional Business continued to deliver strong earnings growth during the year. Segment profit increased by 86.6% year on year to RMB97.2 million, while segment profit margin improved to 23.0%. The significant profit expansion was driven by continued revenue growth, disciplined cost management and improved operating efficiency, indicating that operating leverage is increasingly being realized as the business scales.

The segment also achieved a key milestone in its globalization strategy. In March 2026, DCwire^® received 510(k) clearance from the U.S. Food and Drug Administration, marking the Group’s first regulatory approval in the United States. This milestone validates the competitiveness of the Group’s products and establishes a foundation for further expansion into global markets.

TAVR Business: Leadership Reinforced with Expansion into New Indications

The Group maintained its leading position in China’s TAVR market and continued to expand its commercialization footprint. During the year, revenue from TAVR-related products increased by 11.6% year on year to RMB290.1 million. Total implant volume reached approximately 3,900 units, up 14.4% year on year, while the Group’s products were adopted by more than 780 hospitals, including approximately 130 newly added hospitals during the year.

The Group’s Taurus product family continued to gain strong clinical recognition in the treatment of aortic stenosis, supported by a comprehensive portfolio spanning core and premium offerings. At the same time, the approval of TaurusTrio^® (the Group’s localized product licensed from the JenaValve Trilogy^TM THV System for Greater China) in December 2025 for the treatment of symptomatic, severe aortic regurgitation marked a major strategic milestone. This approval expands the Group’s valve platform from a single-indication focus to a broader multi-indication platform, opening new growth opportunities and strengthening its long-term competitive positioning.

Pipeline Momentum and Multiple Near-Term Catalysts

The Group continued to make steady progress across its pipeline, supporting the next phase of growth. In China, registration applications were submitted for TaurusNXT^®, the Group’s next-generation durability-enhanced TAVR product, and GeminiOne^®, its transcatheter edge-to-edge repair (TEER) system. Patient enrollment for the registration clinical trial of HighLife^®, the Group’s licensed-in trans-septal mitral valve replacement system continued to accelerate, while ReachTact^®, the Group’s robotic-assisted TAVR system, entered registration clinical trial phase.

Globally, GeminiOne^® has been submitted for EU MDR CE Mark registration, while other pipeline programs continue to advance through clinical development.

As of the end of 2025, seven of the Group’s transcatheter valve therapeutic products had been included in the National Medical Products Administration (NMPA) Innovative Medical Device Special Review Procedure, ranking first in the industry and highlighting the Group’s strong innovation capabilities.

Management Commentary

Dr. Yi Zhang, Chairman and CEO of Peijia Medical, commented:

“2025 was a year of steady progress and strengthening fundamentals for Peijia. Our Transcatheter Valve Therapeutic Business continued to expand its commercialization platform and growth potential, while our Neurointerventional Business delivered accelerated profit growth and is becoming an increasily important contributor to the Group’s earnings.

Looking ahead to 2026, we see both new opportunities and higher expectations. We will remain focused on disciplined execution, continuous innovation and long-term value creation as we advance into the next stage of growth.”

Note:

About the Company

Peijia Medical (9996.HK) was established in 2012 and is headquartered in Suzhou, China. Peijia Medical focuses on the high-growth interventional procedural medical device market in China and aims to become a world-renowned medical device platform that provides comprehensive treatment solutions for structural heart and neurovascular diseases. The Company now has four TAVR systems and near twenty neurointerventional devices commercialized in China and various innovative product candidates at different stage of development. For more information about Peijia visit https://www.peijiamedical.com/.

• Reinforcing long-term commitment to embedding sustainability across operations and partnerships
• Continuing to support clients in delivering high-quality, life-saving medicines to patients worldwide

INCHEON, South Korea, March 26, 2026 /PRNewswire/ — Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), received recognition at the 2026 CDMO Leadership Awards presented by Outsourced Pharma and Life Science Connect. The company was awarded the Sustainability Leadership Award, a jury-selected distinction recognizing efforts to advance sustainable practices across its operations and value chain. Samsung Biologics was also named “Best in Class” in Cultural Fit in the ‘Biologics—Large CDMOs’ category, reflecting its strong, collaborative partnerships built on shared goals and close alignment with client needs.

The CDMO Leadership Awards recognize top-performing development and manufacturing service providers based on global client feedback across areas such as facilities, innovation, technical expertise, and manufacturing capabilities. Samsung Biologics has been consistently recognized at the CDMO Leadership Awards, supported by strong client feedback on its ability to deliver reliable execution and maintain consistent service quality. In addition, this year’s Jury Awards are determined by an independent panel of industry experts, informed by survey data and broader industry input.

Attending the awards ceremony in New York on the sidelines of DCAT Week, Samsung Biologics said the recognition reflects the company’s ongoing efforts to maintain stable, resilient, and sustainable practices to support client programs.

“Sustainability is a core value at Samsung Biologics and guides how we pursue excellence throughout our business and partnerships,” said John Rim, President and CEO of Samsung Biologics, who also serves as champion for the Sustainable Markets Initiative (SMI) Supply Chains Working Group. “This recognition reflects the trust our clients and partners continue to place in us, as well as the dedication of our teams who consistently strive to integrate sustainable practices across our operations. We will continue to advance these efforts in close collaboration with our partners, supporting their long-term goals and the delivery of high-quality, life-saving medicines to patients worldwide.”

Samsung Biologics also recently achieved a Platinum rating from EcoVadis, awarded to top-performing companies worldwide in sustainability practices. The company has also implemented a product carbon footprint (PCF) system, which has been independently validated to support transparent and consistent emissions measurement. While continuing its role as a Champion of the SMI Health Systems Task Force, Samsung Biologics will further strengthen engagement with global suppliers in decarbonization efforts and the development of more resilient value chains.

About Samsung Biologics Co., Ltd.
Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing.

With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II, and 60,000 liters from the planned acquisition of a manufacturing facility in Rockville, Maryland, U.S. upon deal closure at the end of Q1 2026, Samsung Biologics continues to expand its manufacturing footprint. The company has also secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities.

Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics

By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity.

Samsung Biologics’ global manufacturing and commercial network spans Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region.

Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health.

For more information, visit https://samsungbiologics.com/

Media contacts 
Samsung Biologics 
Claire Kim, Senior Director cair.kim@samsung.com
Becky Lee, Director brite.lee@samsung.com

• Interline cooperation launched with Star Alliance member Thai Airways
• Expands connectivity via Bangkok hub across Southeast Asia and India, targeting transit demand to the Americas

SEOUL, South Korea, March 26, 2026 /PRNewswire/ — Air Premia, Korea’s only hybrid service carrier, announced that it has entered an interline partnership with Thailand’s national flag carrier, Thai Airways, with joint transportation services set to commence on March 30.

Through this collaboration, Air Premia aims to capture transit demand from Southeast Asia and India traveling to the Americas via Incheon, while Thai Airways will be able to expand its network into the U.S. market through Air Premia’s long-haul routes from Incheon. Currently, there are no direct flights connecting Thailand and the United States.

Under the agreement, the two airlines will offer joint ticketing. Passengers will benefit from seamless travel across both carriers’ networks with a single booking, enabling convenient access to a wider range of destinations.

Air Premia currently operates long-haul routes from Incheon to major U.S. destinations, including Los Angeles, New York, San Francisco, Honolulu, and Washington, D.C. (planned), as well as regional routes across Asia, including Narita, Bangkok, Da Nang, and Hong Kong.

Thai Airways, the largest full-service carrier in Thailand, operates eight domestic routes and 54 international routes across Asia, Europe, and Oceania from its hub at Bangkok’s Suvarnabhumi Airport. It is also a founding member of the Star Alliance, the world’s largest airline alliance.

Through this interline partnership, Air Premia’s Americas routes will be connected to Thai Airways’ extensive network, including key domestic destinations in Thailand such as Phuket and Chiang Mai, as well as major cities across Southeast Asia—including Kuala Lumpur, Singapore, Jakarta, and Hanoi—and India, including New Delhi, Mumbai, and Chennai.

On the Incheon–Bangkok route, both airlines operate services, with Thai Airways offering three daily flights. This increased frequency is expected to provide greater flexibility and more options for passengers, further supporting the growth of transit demand to the Americas.

“Through this interline partnership with Thai Airways, a Star Alliance member, we expect to expand transit demand from Southeast Asia and India to the Americas,” said an Air Premia official. “We will continue to broaden travel options for our customers by strengthening cooperation with various airline partners.”